Articles Published in 2013

Stem Cell Therapeutics acquires license option

Monday, August 12, 2013 01:15 PM

Stem Cell Therapeutics (SCT), a biopharmaceutical company developing cancer stem cell-related therapeutics, has entered into an option agreement to exclusively license worldwide rights to a series of prostate cancer stem cell assets from the University of York, U.K. The assets originate from research funded by and conducted at Yorkshire Cancer Research (YCR) under the direction of professor Norman Maitland.

More... »

WorldCare Clinical launches oncology imaging studies service

Monday, August 12, 2013 01:14 PM

CRO WorldCare Clinical (WCC) has launched a service that enables simultaneous capture and analysis of both standard tumor assessments, including Response Evaluation Criteria in Solid Tumors (RECIST) and the immune-related response criteria (irRC). WCC’s method has been validated and is being used to evaluate new immune-related treatments.  

More... »

Nuevolution launches collaboration

Monday, August 12, 2013 01:12 PM

Nuevolution is collaborating with Duke University, the Howard Hughes Medical Institute and Lexicon Pharmaceuticals for the investigation of the biological mechanism of action of a specified GPCR drug target. The Principal Investigator for Duke University and the Howard Hughes Medical Institute is Robert J. Lefkowitz, a Duke faculty member, HHMI employee and Nobel Laureate in Chemistry 2012.

More... »

Catabasis announces successful phase I trial

Friday, August 9, 2013 02:09 PM

Catabasis Pharmaceuticals has announced preliminary data from a phase I trial of CAT-2003, an oral SMART Linker conjugate constructed using the company's proprietary technology, demonstrated a significant reduction in fasting and post-prandial triglyceride levels. CAT-2003 also had positive effects on other biomarkers, including reductions in apolipoprotein C-III (ApoC-III), a negative regulator of lipoprotein lipase, and apolipoprotein B (ApoB), the lipoprotein associated with VLDL and LDL cholesterol. In addition, reductions in plasma PCSK9 levels and LDL cholesterol were observed.

More... »

Boehringer, Lilly enroll first patient in type 2 diabetes trial

Friday, August 9, 2013 02:07 PM

Boehringer Ingelheim Pharmaceuticals and Eli Lilly have announced enrollment of the first patient into a cardiovascular (CV) and renal outcomes trial for linagliptin (tradjenta) tablets.

More... »

Aeterna Zentaris announces first patient dosed in phase III endometrial cancer trial

Friday, August 9, 2013 02:05 PM

Aeterna Zentaris has announced the first patient has been recruited and dosed for the phase III ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) trial in women with endometrial cancer resistant to platinum/taxane-based chemotherapy.

More... »

inVentiv Health Clinical expands executive team

Friday, August 9, 2013 02:02 PM

CRO inVentiv Health Clinical has appointed Dawn Anderson president of phase II-IV development, Martin Birkhofer chief medical officer and Richard Shimota chief financial officer.

More... »

Harlan CRS Cytotest Cell Research in EU-NETVAL

Friday, August 9, 2013 01:58 PM

Germany-based Harlan Contract Research Services (CRS) Cytotest Cell Research has been selected for inclusion in the E.U. Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL). EU-NETVAL provides support for the E.U. Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) to develop methods to reduce, refine or replace animals used for scientific purposes.

More... »

Alan Copa joins Novum as vice president

Friday, August 9, 2013 01:56 PM

Dr. Alan Copa has joined the leadership team of CRO Novum Pharmaceutical Research Services as vice president. Previously, Copa was chief scientific officer of PRACS Institute. In his 20-year tenure at the company, Copa had numerous clinical and operational lead roles, and was Principal Investigator on 1,000 projects spanning early phase, dermatology and pharmacokinetics.

More... »

U.K. grants $192.4 million to researchers

Friday, August 9, 2013 01:20 PM

The National Institute for Health Research (NIHR) has granted $192.4 million to health researchers across the U.K. to tackle the nation’s most pressing health problems.

More... »